Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Rhea-AI Summary

Labcorp (NYSE: LH) and Illumina on March 18, 2026 expanded a collaboration to broaden precision oncology testing access via distributed IVD kits, new CGP and WGS test development, and evidence generation to support payer coverage.

Plans include exploring co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive, and continuing joint studies (one evaluated >7,600 NSCLC samples, detecting actionable variants in >72%).

Positive

• CGP detected actionable variants in >72% of 7,600 NSCLC samples
• Co-commercialization of FDA-authorized PGDx elio plasma focus Dx and FDA-approved TruSight Oncology Comprehensive
• Distributed IVD offering intended to expand testing access in hospitals and community systems

Negative

• Execution risk from developing and launching new technologies
• Reliance on partner performance and multiparty collaboration complexity
• Payer coverage remains uncertain despite planned evidence-generation efforts

News Market Reaction – ILMN

+1.75%

1 alert

+1.75% News Effect

On the day this news was published, ILMN gained 1.75%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

NSCLC tumor samples: more than 7,600 samples Actionable variants rate: more than 72% of patient tumors Joint oncology publications: 8 publications +1 more

4 metrics

NSCLC tumor samples more than 7,600 samples Frontiers of Oncology collaborative study

Actionable variants rate more than 72% of patient tumors NSCLC study with Illumina CGP detecting variants with targeted therapy or trial

Joint oncology publications 8 publications Joint Illumina–Labcorp oncology work since 2022

Posters and presentations 18 posters and presentations Industry conference outputs from Illumina–Labcorp oncology collaboration

Market Reality Check

Price: $124.33 Vol: Volume 1,362,182 is below...

low vol

$124.33 Last Close

Volume Volume 1,362,182 is below the 20-day average of 2,002,704 (relative volume 0.68), suggesting a moderate reaction. low

Technical Shares at $120.84 are trading above the 200-day MA of $112.41, and about 22.3% below the 52-week high of $155.529.

Peers on Argus

ILMN is up 1.31% with mixed peer moves: WAT up 1.43%, LH up 2.22%, while MEDP an...

ILMN is up 1.31% with mixed peer moves: WAT up 1.43%, LH up 2.22%, while MEDP and DGX are down and PKI is flat, pointing to a stock-specific response to the collaboration news.

Historical Context

5 past events · Latest: Mar 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	Preventive genomics consortium	Positive	+0.5%	Consortium with Veritas to integrate whole-genome sequencing into preventive care.
Mar 5	Genomic discovery expansion	Positive	-0.6%	Alliance for Genomic Discovery expansion to 312,000 genomes and new proteomics cohort.
Feb 27	Rare disease partnership	Positive	+5.5%	Collaboration with Florida IPRD to accelerate rare-disease testing via WGS.
Feb 25	Oncology tech showcase	Positive	-0.8%	Customer oncology breakthroughs using spatial transcriptomics and multiomics technologies.
Feb 24	Product launch	Positive	+2.0%	Launch of TruPath Genome whole‑genome solution with improved accuracy and workflow.

Pattern Detected

Recent partnership and product news has produced mixed reactions, with both gains and declines following generally positive announcements.

Recent Company History

Over recent weeks, Illumina has repeatedly highlighted expansion initiatives in genomics. On Feb 24, it launched TruPath Genome with a listed price of $395 and a throughput of 16 genomes/day, followed by oncology-focused multiomics advances on Feb 25 and a rare‑disease sequencing collaboration on Feb 27. Early March brought growth of the Alliance for Genomic Discovery to 312,000 whole genomes and a preventive genomics consortium on Mar 16. Today’s Labcorp collaboration fits this pattern of broadening clinical and oncology applications for Illumina technology.

Market Pulse Summary

This announcement deepens Illumina’s oncology footprint through an expanded Labcorp collaboration, t...

Analysis

This announcement deepens Illumina’s oncology footprint through an expanded Labcorp collaboration, targeting broader access to CGP, WGS, and liquid biopsy testing. The companies highlight real-world evidence, with Illumina CGP identifying variants linked to targeted therapies or trials in more than 72% of over 7,600 NSCLC tumors. This builds on eight joint oncology publications and multiple posters. Investors may watch for adoption by hospitals, payer coverage decisions, and further clinical-utility data to gauge long-term impact.

Key Terms

next-generation sequencing, liquid biopsy, in vitro diagnostic, comprehensive genomic profiling, +3 more

7 terms

next-generation sequencing medical

"advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions"

Next-generation sequencing is a set of laboratory techniques that read large amounts of DNA or RNA quickly and cheaply by processing millions of short genetic fragments in parallel, rather than one at a time. For investors, it matters because faster, lower-cost genetic data powers drug discovery, diagnostic tests and personalized medicine, creating scalable revenue opportunities and competitive advantages for companies that own the technology or services.

liquid biopsy medical

"liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight"

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

in vitro diagnostic medical

"in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP) and whole-genome"

In vitro diagnostics are tests, instruments and kits used to analyze samples taken from the body—such as blood, urine or swabs—outside the body (in a lab or cartridge) to detect disease, infections, genetic traits or other biological signs. Investors care because these products generate sales, recurring revenue from consumable test kits, and value that hinges on test accuracy, regulatory approvals and reimbursement policies; like a home pregnancy test but for many medical conditions.

comprehensive genomic profiling medical

"IVD tests for comprehensive genomic profiling (CGP) and whole-genome sequencing"

Comprehensive genomic profiling is a laboratory test that reads a large portion of a tumor’s or patient’s DNA to find many possible genetic changes at once, like using a detailed map instead of a single street view. For investors, it matters because results can guide targeted treatments, influence demand for companion diagnostics and drugs, and affect regulatory approvals and reimbursement, all of which can drive clinical adoption and commercial value.

whole-genome sequencing medical

"IVD tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS)"

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

companion diagnostic medical

"opportunities for companion diagnostic (CDx) development, supporting both tissue and liquid"

A companion diagnostic is a medical test designed to identify which patients are likely to benefit from a specific drug or medical treatment, much like a key that shows whether a particular lock will open. For investors, these tests matter because they can increase a drug’s chances of approval and market uptake, create a separate revenue stream, and reduce commercial risk by matching treatments to the patients most likely to respond.

non-small cell lung cancer medical

"researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

"By deepening our collaboration, we'll continue to leverage the strengths of our respective teams to innovate and improve access to critical biomarker testing for patients with cancer," said Traci Pawlowski, vice president of Clinical Product Development at Illumina. "Our longstanding collaboration is rooted in a shared vision to advance precision oncology through groundbreaking research and leading-edge technologies."

New test development is expected to span advanced oncology research and in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS). These solutions will aim to address areas of unmet needs in precision oncology and help bridge existing testing gaps.

As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive for solid tumor profiling. Together, these distributed IVD test kits are intended to expand access to both tissue and liquid biopsy testing for hospitals and community health systems—bringing advanced biomarker testing closer to patients and helping to provide more specific diagnoses and identify eligibility for targeted treatments and clinical trials. This distributed offering also aims to provide pharmaceutical companies with differentiated opportunities for companion diagnostic (CDx) development, supporting both tissue and liquid biopsy needs for targeted therapy approvals.

"This collaboration reflects Labcorp and Illumina's shared commitment to improving cancer care through innovation and access," said Shakti Ramkissoon, MD, PhD, MBA, vice president and medical lead for oncology at Labcorp. "Building on our longstanding medical and scientific collaborations and our ongoing efforts to generate clinical evidence and expand access to advanced genomics, we are combining our expertise to deliver transformative testing solutions that support more timely, equitable cancer care."

Illumina and Labcorp will also continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption. In a collaborative study published in Frontiers of Oncology, researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples. The study applied Illumina CGP to demonstrate its coverage and utility in detecting known and novel genomic features of NSCLC. Results showed that CGP detected variants with a current targeted therapy or clinical trial in more than 72% of patient tumors.

This is one of eight joint publications in oncology between Illumina and Labcorp since 2022, along with 18 posters and presentations made at industry conferences.

"Expanding access to advanced genomic testing is essential to delivering personalized cancer care," said Pawlowski. "Together with Labcorp, we are accelerating innovation to bring critical insights closer to patients and enable better outcomes across diverse care settings."

Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.

About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

Contacts 

Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com

Media:
Christine Douglass
PR@illumina.com

View original content:https://www.prnewswire.com/news-releases/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing-302716715.html

SOURCE Illumina, Inc.

FAQ

What did Labcorp (LH) and Illumina announce on March 18, 2026 about precision oncology testing?

They announced an expanded collaboration to develop distributed IVD kits, CGP and WGS tests, and evidence-generation efforts to broaden access to biomarker testing. According to Labcorp and Illumina, the plan includes co-commercialization exploration for specific FDA-authorized and FDA-approved assays.

How will the proposed co-commercialization affect Labcorp (LH) testing availability in hospitals and community systems?

The co-commercialized distributed IVD kits aim to bring tissue and liquid biopsy testing closer to patients in hospitals and community systems. According to the companies, this is intended to increase local access to advanced biomarker testing and support diagnosis and trial eligibility.

What did the joint study between Labcorp and Illumina find about NSCLC genomic profiling?

The collaborative study evaluated more than 7,600 NSCLC tumor samples and found CGP detected variants linked to targeted therapy or trials in over 72% of tumors. According to the companies, this supports CGP's coverage and clinical utility in NSCLC.

Will the expanded Labcorp (LH) and Illumina collaboration guarantee payer coverage for new oncology tests?

No, payer coverage is not guaranteed; the collaboration aims to generate evidence to facilitate coverage but uncertainty remains. According to Labcorp and Illumina, they will pursue studies and data to support reimbursement decisions over time.

What are the main risks investors should note about the Labcorp (LH) and Illumina collaboration announced March 18, 2026?

Key risks include challenges in research, development and product launches, and reliance on partner performance in multiparty collaborations. According to the companies, these factors could cause actual outcomes to differ materially from forward-looking expectations.